PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION [PDF]
Рациональная фармакотерапия в кардиологии, 2015 Disadvantages of vitamin K antagonist warfarin and the benefits of new anticoagulants, including dabigatran etexilate, in the stroke prevention in patients with atrial fibrillation are considered.
E. D. Kosmacheva +6 more
doaj +4 more sources
Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations [PDF]
Российский кардиологический журнал, 2019 The review discusses the problem of patient-oriented choice of anticoagulants for nonvalvular atrial fibrillation (AF). The efficacy and safety profile of dabigatran etexilate and a group of patients with advantage of dabigatran application: patients ...
E. I. Baranova, Zhanna Kobalava
doaj +2 more sources
Recovery of Visual Function after Administration of Dabigatran Etexilate
Case Reports in Ophthalmology, 2014 A 46-year-old Caucasian female underwent pars plana vitrectomy (ppv) for retinal detachment. After the procedure, the patient could only distinguish hand movements; the condition was tentatively diagnosed as nonarteritic anterior ischemic optic ...
Carl-Ludwig Schönfeld +6 more
doaj +2 more sources
Drug Design, Development and Therapy, 2015 Michael R Preusch,1,2 Nicholas Ieronimakis,1 Errol S Wijelath,3 Sara Cabbage,1 Jerry Ricks,1 Florian Bea,2 Morayma Reyes,1 Joanne van Ryn,4 Michael E Rosenfeld1,5 1Department of Pathology, University of Washington, Seattle, WA, USA; 2Department of ...
Preusch MR +8 more
doaj +1 more source
DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER [PDF]
Рациональная фармакотерапия в кардиологии, 2016 Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular atrial fibrillation is considered. Results of randomized clinical trials on efficacy and safety of dabigatran in various doses are discussed.
I. S. Yavelov
doaj +2 more sources
Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease [PDF]
Case Reports in Medicine, 2013 Introduction. Dabigatran is an oral direct thrombin inhibitor which has been approved for prophylaxis of stroke in patients with atrial fibrillation. The use of dabigatran etexilate increased rapidly due to many benefits.
Joonseok Kim +6 more
doaj +2 more sources
An Unusual Side Effect of Dabigatran Etexilate Use - Acute Renal Failure
Eurasian Journal of Emergency Medicine, 2019 Dabigatran etexilate is a prodrug with anticoagulant effect through inhibition of thrombin. Although it does not require laboratory monitoring and has minimal food-drug interaction, its disadvantages are bleeding, common GIS-related side effects and the ...
Ekim Sağlam Gürmen, Adnan Bilge
doaj +2 more sources
Translation of a physiologically-based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post-partum women. [PDF]
Br J Clin PharmacolAims To translate a PBPK model developed for the direct oral anticoagulant, dabigatran etexilate, the prodrug of dabigatran, based on data obtained from healthy men to healthy non‐pregnant, pregnant and post‐partum women. To evaluate safety and efficacy of dabigatran etexilate in post‐partum women using simulations and design a future clinical study to
Ogungbenro K +3 more
europepmc +2 more sources
Geographical variability in dabigatran dosing within New Zealand. [PDF]
Intern Med JAbstract Dabigatran etexilate is an oral anticoagulant with increased risk of bleeding at high drug exposure. It is available in three capsule strengths (75, 110 and 150 mg). We analysed New Zealand dispensing data from 2019 to 2023 to compare use between health districts. Overall use was similar across districts.
Berryman LT +4 more
europepmc +2 more sources
Dabigatran etexilate and COVID-19
, 2021 Thrombotic complications are frequent in COVID-19. There is evidence supporting the use of prophylactic dose low molecular weight heparin (LMWH) as prophylaxis for venous thromboembolism in critically ill patients. Indeed, all patients with COVID-19 that
Domina Petric
core +1 more source